IRVINE, CA, and HERSTAL, BELGIUM – March 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2023.
Michael K. McGarrity, CEO of mdxhealth, commented: “Our fourth quarter and full year 2023 results reflect our continued commitment to commercial execution and operational discipline that has driven significant gross margin expansion across our business. With each passing quarter, we continue to build on our position as a leading precision diagnostics company rooted in our industry-leading technology, focus on the highest quality customer experience, and our unwavering commitment towards improving patient outcomes. We remain well positioned to build upon this success as we actively evaluate multiple, high-growth opportunities that could further strengthen and complement our existing menu. In 2024, we expect to deliver continued topline growth and operating execution that will lead to adjusted EBITDA profitability in the first half of 2025.”
Key Highlights:
Financial review for the fourth quarter and year ended December 31, 2023
| USD in ‘000 (except per share data) Unaudited | Three months ended December 31 | Twelve months ended December 31 | ||||||
| 2023 | 2022 | % Change | 2023 | 2022 | % Change | |||
| Revenue | 19,398 | 12,891 | 50% | 70,193 | 37,054 | 89% | ||
| Cost of goods | (6,727) | (5,667) | 19% | (26,264) | (17,835) | 47% | ||
| Gross Profit | 12,671 | 7,224 | 75% | 43,929 | 19,219 | 129% | ||
| Operating expenses | (18,977) | (16,171) | 17% | (71,256) | (57,119) | 25% | ||
| Operating loss | (6,306) | (8,947) | (30%) | (27,327) | (37,900) | (28%) | ||
| Net loss | (10,720) | (12,438) | (14%) | (43,100) | (44,044) | (2%) | ||
| Basic and diluted loss per share | (0.39) | (0.76) | (48%) | (1.66) | (2.78) | (40%) | ||
Fourth Quarter 2023 Financial Results
Revenue increased 50% to $19.4 million compared to $12.9 million for the prior year. Revenue was comprised of $8.8 million from GPS, $5.9 million from Confirm mdx, $3.2 million from Resolve mdx, and $1.3 million from Select mdx.
Gross margins were 65.3% compared to 56.0% for the prior year, an improvement of 9.3 percentage points attributed to contribution from Select mdx reimbursement, coupled with cost management and expanded coverage across our menu.
Operating expenses increased 17% to $19.0 million compared to $16.2 million for the prior year, driven by increases in R&D expense, increased sales and marketing activity from the GPS acquisition, as well as $1.7 million of non-recurring expenses, primarily attributed to the transition to a sole listing on NASDAQ.
Net loss decreased 14% to $10.7 million compared to $12.4 million for the prior year, driven by the factors mentioned above, partially offset by an increase of $2.1 million in financial expenses, of which $1.8 million was non-cash.
Full Year 2023 Financial Results
Revenue increased 89% to $70.2 million compared to $37.1 million for the prior year. Excluding GPS, revenue increased 42% to $39.3 million compared to $27.7 million for the prior year. Revenue was comprised of $30.9 million from GPS, $24.8 million from Confirm mdx, $9.7 million from Resolve mdx, and $4.5 million from Select mdx.
Gross margins were 62.6% compared to 51.9% for the prior year, an improvement of 10.7 percentage points attributed to contribution from Select mdx reimbursement, cost management, expanded coverage across our menu, and a higher contribution from GPS to total revenue.
Operating expenses increased 25% to $71.3 million compared to $57.1 million for the prior year, primarily driven by the acquisition of the GPS test in August 2022, and includes $2.6 million of non-recurring expenses, primarily attributed to the transition to a sole listing on NASDAQ.
Net loss decreased 2% to $43.1 million compared to $44.0 million for the prior year, driven by the factors mentioned above, partially offset by an increase of $11.4 million in financial expenses, of which $9.1 million was non-cash and primarily related to the GPS contingent consideration.
Cash and cash equivalents as of December 31, 2023, were $22.4 million.
Business Update and Outlook for 2024
The Company is maintaining its previously issued 2024 revenue guidance of $79-81 million and confirms its view of expected adjusted EBITDA profitability in the first half of 2025.
Conference Call
Michael K. McGarrity, Chief Executive Officer and Ron Kalfus, Chief Financial Officer, will host a conference call and Q&A session today at 4:30 PM EST / 22:30 CET. The call will be conducted in English and a replay will be available for 30 days.
To participate in the conference call, please select your phone number below:
United States: 1-888-886-7786
Belgium: 0800 76018
The Netherlands: 0800 022 7908
United Kingdom: 1-800-652-2435
To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled
start time.
About mdxhealth
Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
This email address is being protected from spambots. You need JavaScript enabled to view it.
LifeSci Advisors (IR & PR)
US: +1 949 271 9223
This email address is being protected from spambots. You need JavaScript enabled to view it.
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “potential,” “expect,” “will,” “goal,” “next,” “potential,” “aim,” “explore,” “forward,” “future,” and “believes” as well as similar expressions. Forward-looking statements contained in this release include, but are not limited to, statements regarding expected future operating results; expectations for development of new or improved products and services and their impact on patients; our strategies, positioning, resources, capabilities and expectations for future events or performance; and the anticipated benefits of our acquisitions, including estimated synergies and other financial impacts. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, product development efforts, our strategies, positioning, resources, capabilities and expectations for future events or performance. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products; the acceptance of our products and services by healthcare providers; our ability to achieve and maintain adequate levels of coverage or reimbursement for our current and future solutions we commercialize or may seek to commercialize; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; timing, progress and results of our research and development programs; the period over which we estimate our existing cash will be sufficient to fund our future operating expenses and capital expenditure requirements; the possibility that the anticipated benefits from our business acquisitions like our acquisition of the Oncotype DX® GPS prostate cancer business will not be realized in full or at all or may take longer to realize than expected; and the amount and nature of competition for our products and services. Other important risks and uncertainties are described in the Risk Factors sections of our most recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange Commission. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
Non-IFRS Measures
The Company’s reference to adjusted EBITDA is a forward-looking statement about the Company’s future financial performance, and is a non-IFRS measure that excludes a number of expense items that are included in net loss, including adjustments for items like stock-based compensation, acquisition and integration costs, impairment of long-lived assets, fair-value adjustment, loan extinguishment costs, as well as other non-operating, non-recurring expenses that are difficult to predict for future periods because the nature of the adjustments pertain to events that have not yet occurred. As a result, positive adjusted EBITDA may be achieved while a significant net loss persists. Non-IFRS financial information has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with IFRS, and such information is referenced for supplemental information purposes only. Management does not forecast many of the excluded items for internal use, as these are difficult to predict for future periods because the nature of the adjustments pertain to events that have not yet occurred. Information reconciling forward-looking non-IFRS measures to IFRS measures is therefore not available without unreasonable effort, and is not provided. The occurrence, timing, and amount of any of the items excluded from IFRS to calculate non-IFRS measures could significantly impact the Company's IFRS results.
NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark, and all other trademarks and service marks, are the property of their respective owners.
| MDxHealth SA and Subsidiaries |
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| In thousands of $ (except per share amounts) | 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Revenues | $ | 19,398 | $ | 12,891 | $ | 70,193 | $ | 37,054 | ||||||||
| Cost of goods & services sold | (6,727 | ) | (5,667 | ) | (26,264 | ) | (17,835 | ) | ||||||||
| Gross profit | 12,671 | 7,224 | 43,929 | 19,219 | ||||||||||||
| Research and development expenses | (1,829 | ) | (799 | ) | (6,376 | ) | (5,497 | ) | ||||||||
| Selling and marketing expenses | (9,484 | ) | (8,467 | ) | (36,915 | ) | (25,704 | ) | ||||||||
| General and administrative expenses | (6,730 | ) | (5,746 | ) | (23,010 | ) | (23,308 | ) | ||||||||
| Amortization of intangible assets | (1,127 | ) | (1,559 | ) | (4,494 | ) | (3,169 | ) | ||||||||
| Other operating (expense) income, net | 193 | 400 | (461 | ) | 559 | |||||||||||
| Operating loss | (6,306 | ) | (8,947 | ) | (27,327 | ) | (37,900 | ) | ||||||||
| Financial expenses, net | (4,413 | ) | (3,363 | ) | (15,772 | ) | (6,144 | ) | ||||||||
| Loss before income tax | (10,719 | ) | (12,310 | ) | (43,099 | ) | (44,044 | ) | ||||||||
| Income tax | (1 | ) | (128 | ) | (1 | ) | 0 | |||||||||
| Loss for the period | $ | (10,720 | ) | $ | (12,438 | ) | $ | (43,100 | ) | $ | (44,044 | ) | ||||
| Loss per share attributable to parent | ||||||||||||||||
| Basic and diluted | $ | (0.39 | ) | $ | (0.76 | ) | $ | (1.66 | ) | $ | (2.78 | ) | ||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
| In thousands of $ | December 31, 2023 | December 31, 2022 | ||||||||
| ASSETS | ||||||||||
| Non-current assets | ||||||||||
| Goodwill | $ | 35,926 | $ | 35,926 | ||||||
| Intangible assets | 44,337 | 46,166 | ||||||||
| Property, plant and equipment | 4,956 | 3,791 | ||||||||
| Right-of-use assets | 4,989 | 4,103 | ||||||||
| Financial assets | 763 | - | ||||||||
| Total non-current assets | 90,971 | 89,986 | ||||||||
| Current assets | ||||||||||
| Inventories | 2,779 | 2,327 | ||||||||
| Trade receivables | 11,088 | 9,357 | ||||||||
| Prepaid expenses and other current assets | 1,914 | 1,962 | ||||||||
| Cash and cash equivalents | 22,380 | 15,503 | ||||||||
| Total current assets | 38,161 | 29,149 | ||||||||
| TOTAL ASSETS | $ | 129,132 | $ | 119,135 | ||||||
| EQUITY | ||||||||||
| Share capital | $ | 173,931 | $ | 133,454 | ||||||
| Issuance premium | 153,177 | 153,177 | ||||||||
| Accumulated deficit | (331,446 | ) | (288,346 | ) | ||||||
| Share-based compensation | 12,139 | 11,474 | ||||||||
| Translation reserve | (593 | ) | (444 | ) | ||||||
| Total equity | 7,208 | 9,315 | ||||||||
| LIABILITIES | ||||||||||
| Non-current liabilities | ||||||||||
| Loans and borrowings | 35,564 | 34,914 | ||||||||
| Lease liabilities | 3,578 | 3,091 | ||||||||
| Other non-current financial liabilities | 63,259 | 53,537 | ||||||||
| Total non-current liabilities | 102,401 | 91,542 | ||||||||
| Current liabilities | ||||||||||
| Loans and borrowings | 643 | 616 | ||||||||
| Lease liabilities | 1,480 | 1,172 | ||||||||
| Trade payables | 8,811 | 10,178 | ||||||||
| Other current liabilities | 5,694 | 3,985 | ||||||||
| Other current financial liabilities | 2,895 | 2,327 | ||||||||
| Total current liabilities | 19,523 | 18,278 | ||||||||
| Total liabilities | 121,924 | 109,820 | ||||||||
| TOTAL EQUITY AND LIABILITIES | $ | 129,132 | $ | 119,135 | ||||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
| Year Ended December 31, | |||||||||||
| In thousands of $ For the years ended December 31 | 2023 | 2022 | |||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | |||||||||||
| Operating loss | $ | (27,327 | ) | $ | (37,900 | ) | |||||
| Depreciation and amortization | 6,859 | 4,909 | |||||||||
| Impairment | - | 44 | |||||||||
| Share-based compensation | 665 | 867 | |||||||||
| Other non-cash transactions | 421 | (473 | ) | ||||||||
| Cash used in operations before working capital changes | (19,382 | ) | (32,553 | ) | |||||||
| Increase (-) in inventories | (452 | ) | (416 | ) | |||||||
| Increase (-) in receivables | (1,683 | ) | (5,122 | ) | |||||||
| Increase (+) in payables | 20 | 3,973 | |||||||||
| Net cash outflow from operating activities | (21,497 | ) | (34,118 | ) | |||||||
| CASH FLOWS FROM INVESTING ACTIVITIES | |||||||||||
| Purchase of property, plant and equipment | (2,747 | ) | (2,789 | ) | |||||||
| Acquisition and generation of intangible assets | (2,272 | ) | (1,374 | ) | |||||||
| Acquisition of Genomic Prostate Score Business | - | (25,000 | ) | ||||||||
| Interests received | 1,088 | 125 | |||||||||
| Net cash outflow from investing activities | (3,931 | ) | (29,038 | ) | |||||||
| CASH FLOWS FROM FINANCING ACTIVITIES | |||||||||||
| Proceeds from issuance of shares, net of transaction costs | 39,599 | - | |||||||||
| Proceeds from loan obligation | - | 34,291 | |||||||||
| Repayment of loan obligation and debt extinguishment costs | (1,659 | ) | (10,805 | ) | |||||||
| Amendment fee related to GPS asset purchase agreement | (250 | ) | - | ||||||||
| Payment of lease liability | (1,610 | ) | (1,358 | ) | |||||||
| Payment of interest | (3,610 | ) | (1,412 | ) | |||||||
| Other financial expenses | (190 | ) | - | ||||||||
| Net cash inflow from financing activities | 32,280 | 20,716 | |||||||||
| Net increase (+) / decrease (-) in cash and cash equivalents | 6,852 | (42,440 | ) | ||||||||
| Cash and cash equivalents at beginning of the financial year | 15,503 | 58,498 | |||||||||
| Effect on exchange rate changes | 25 | (555 | ) | ||||||||
| Cash and cash equivalents at end of the financial year | $ | 22,380 | $ | 15,503 | |||||||
| Last Trade: | US$1.62 |
| Daily Change: | 0.05 3.18 |
| Daily Volume: | 400,192 |
| Market Cap: | US$44.210M |
November 06, 2024 October 14, 2024 September 25, 2024 August 21, 2024 August 12, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
